## **Ventilator-Associated Events**

#### Symposium on Prevention of Healthcare-associated Infections in Hospitals and Community Institutions

Infection Control Branch, Centre for Health Protection, Department of Health, Hong Kong

January 19, 2019

Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham and Women's Hospital

# Disclosures

## • Grant funding

- Centers for Disease Control and Prevention
- Massachusetts Department of Public Health
- Royalties
  - UpToDate

# Objectives

## • Why did CDC replace VAP with VAE?

- Limitations of VAP diagnosis
- Implications for prevention
- Implications for surveillance

## • How can we optimize surveillance for VAEs?

- CDC' s online VAE calculator
- Automated implementations


### • How can we best prevent VAEs?

- Early extubation
- Target the specific diseases that typically cause VAEs

Why did CDC replace VAP with VAE?

# The Challenge of VAP Diagnosis

- Many complications of critical care present with the same clinical signs as VAP
  - Radiographic opacities
  - Fever
  - Abnormal white blood cell count
  - Impaired oxygenation
  - Increased pulmonary secretions



"Diffuse patchy airspace disease right greater than left with obliteration of both hemi-diaphragms. Opacities possibly slightly increased since yesterday accounting for changes in patient position and inspiration. This could represent atelectasis, pneumonia, or effusion."

# Sources of fever and infiltrates

- ARDS
- Thromboembolic disease
- Hemorrhage
- Infarction
- Fibrosis
- Carcinoma
- Lymphoma
- Contusion




#### PLUS

Pulmonary edema Atelectasis Contusion Fibrosis

## Accuracy of clinical signs for VAP


Relative to autopsy, systematic review, 14 studies, 655 patients



JAMA 2007; 297:1583

## Accuracy of Clinical Diagnosis of VAP


Relative to 253 autopsies



*J Critical Care* 2010;25:62

### Accuracy of BAL cultures

Relative to histology



Kirtland, *Chest* 1997;112:445 Fabregas, *Thorax* 1999;54:867 Chastre, *Am Rev Respir Dis* 1984;130:924 Torres, *Am J Resp Crit Care Med* 1994;149:324 Marquette, *Am J Resp Crit Care Med* 1995;151:1878 Papazian, *Am J Resp Crit Care Med* 1995;152:1982

## **Implications for Prevention**

# **The Classic Ventilator Bundle**

*Lives* Cam SOME IS NOT A NUMBER, SOON IS NOT A TIME.



Elevate the head of the bed

Daily sedative interruptions


Spontaneous breathing trials

Stress ulcer prophylaxis

DVT prophylaxis

Oral care with chlorhexidine

## **Circularity Between VAP Prevention Practices and the VAP Definition**



### **VAP** Definition

Fever Leukocytosis Purulent Secretions Positive cultures


Oral care with CHG Silver Coated ETT Subglottic secretion drainage Semi-recumbent position etc.

positive cultures and/or
secretions

## Oral Care with Chlorhexidine: Significantly *Lower* VAP Rates

Chlorhexidine							
De Riso et al (1996) <sup>18</sup>	3	173	9	180	3.8%		
Fourrier et al (2000) <sup>13</sup>	5	30	18	30	7-0%		
Houston et al (2002) <sup>20</sup>	4	270	9	291	4-4%		
MacNaughton et al (2004) <sup>22</sup>	32	91	28	88	14-1%		
Grap et al (2004) <sup>14</sup>	4	7	3	5	5.9%		
Fourrier et al (2005) <sup>19</sup>	13	114	12	114	8-3%		
Bopp et al (2006) <sup>17</sup>	0	2	1	3	0-9%		
Koeman et al (2006) <sup>21</sup>	13	127	23	130	9.9%		
Tantipong et al (2008) <sup>23</sup>	5	102	12	105	5-5%		
Scannapieco et al (2009) <sup>26</sup>	14	116	12	59	8-8%		
Bellisimo-Rodriguez et al (2009) <sup>24</sup>	16	64	17	69	10-6%		
Panchabhai et al (2009) <sup>25</sup>	14	88	15	83	9-4%		
Subtotal (95% CI)		1184		1157	88.5%		
Total events	123		159				
Heterogeneity: τ²=0·06, χ²=15·54, df=11 (p=0·16); l²=29%							
Test for overall effect: Z=2-40 (p=0-02)							

Ventilator-Associated Pneumonia



*Lancet Infectious Disease* 2011;11:845

## Oral Care with Chlorhexidine: Significantly <u>*Higher*</u> Mortality Rates


	No of events/total		Mortality	Mortality		
Study	Treatment	Control	Odds ratio, M-H random (95% CI)	Weight (%)	Mortality Odds ratio, M-H random (95% CI)	
Fourier 2000	3/30	7/30		2	0.37 (0.08 to 1.58)	
MacNaughton 2004	29/101	29/93	-	8	0.89 (0.48 to 1.64)	
Fourrier 2005	31/114	24/114		9	1.40 (0.76 to 2.58)	
Koeman 2006	49/127	39/130	-	12	1.47 (0.87 to 2.46)	
Tantipong 2008	36/102	37/105	-	10	1.00 (0.57 to 1.77)	
Scannapieco 2009	19/116	9/59		4	1.09 (0.46 to 2.58)	
Bellissimo-Rodrigues 200	9 35/98	33/96	+	9	1.06 (0.59 to 1.91)	
Munro 2009	69/275	47/272		18	1.60 (1.06 to 2.43)	
Panchabhai 2009	78/224	70/247	+	21	1.35 (0.91 to 2.00)	
Cabov 2010	1/30	3/30		<1	0.31 (0.03 to 3.17)	
Berry 2011	17/71	28/154	<u>+</u>	7	1.42 (0.72 to 2.80)	
Total (95% CI)	367/1288	326/1330		100	1.25 (1.05 to 1.50)	
Test for heterogeneity: $\tau^2 = 0$	0.00, χ <sup>2</sup> =8.4	1, C	0.01 0.1 1 10 1	.00	Odds Ratio	
df=10, P=0.59,   <sup>2</sup> =0%			avours Favo		25 (1.05-1.50)	
Test for overall effect: z=2.		experimental cont	rol			

BMJ 2014;348:g2197

# **Stress Ulcer Prophylaxis**


Randomized controlled trials of ulcer prophylaxis vs placebo in patients getting enteral nutrition

#### Ventilator-associated pneumonia



Significantly higher risk for VAP!





# **Implications for surveillance**

## CDC' s VAP Surveillance Definition

2008

#### Patient must fulfill each of the three categories below:

Chest Radiograph	Any one of the following: 1. New, progressive, or persistent infiltrate 2. Consolidation 3. Cavitation
Systemic Signs	<ul> <li>Any one of the following:</li> <li>1. Temperature &gt;38°C</li> <li>2. WBC &lt;4,000 or &gt;12,000 WBC/mm<sup>3</sup></li> <li>3. For adults 70 years old, altered mental status with no other recognized cause</li> </ul>
Pulmonary Signs	<ul> <li>Any two of the following:</li> <li>1. New onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements</li> <li>2. New onset or worsening cough, or dyspnea, or tachypnea</li> <li>3. Rales or bronchial breath sounds</li> <li>4. Worsening gas exchange, increased oxygen requirements, or increased ventilation demand</li> </ul>

# Complicated


# Labor Intensive

# Subjective

# **Non-Specific**


## Interobserver Agreement in VAP Surveillance

50 ventilated patients with respiratory deterioration



Am J Infect Control 2010:38:237


### 6 Case Vignettes Presented to 43 Reviewers



Crit Care Med 2014;42:497

## Impact of diagnostic technique on VAP rates

53 patients with clinically suspected VAP




# Five Ways to lower VAP rates

Without meaningfully changing patient care

- 1. Narrowly interpret subjective clinical signs
- 2. Narrowly interpret radiographs
- 3. Seek consensus between multiple surveyors
- 4. Allow clinicians to veto surveillance determinations
- 5. Increase use of quantitative BAL for diagnosis


### **U.S. National VAP Rates**

United States, 2004-2012




Source: CDC NNIS and NHSN

## U.S. National VAP Rates, 2005-2013



JAMA 2016;316:2427-2429







# American Thoracic Society

We help the world breathe®



The Intensive Care Professionals









Council of State and Territorial Epidemiologists

Leaders in Applied Public Health Epidemiology





# Developing a New, National Approach to Surveillance for Ventilator-Associated Events\*

Shelley S. Magill, MD, PhD<sup>1</sup>; Michael Klompas, MD, MPH<sup>2,3,4</sup>; Robert Balk, MD<sup>5,6</sup>; Suzanne M. Burns, RN, ACNP, MSN, RRT<sup>6,7</sup>; Clifford S. Deutschman, MS, MD<sup>6,8</sup>; Daniel Diekema, MD<sup>9,10</sup>; Scott Fridkin, MD<sup>1</sup>; Linda Greene, RN, MPS<sup>11,12</sup>; Alice Guh, MD, MPH<sup>1</sup>; David Gutterman, MD<sup>6,13</sup>; Beth Hammer, RN, MSN, ANP-BC<sup>6,14</sup>; David Henderson, MD<sup>15</sup>; Dean Hess, PhD, RRT<sup>16,17,18</sup>; Nicholas S. Hill, MD<sup>6,19</sup>; Teresa Horan, MPH<sup>1</sup>; Marin Kollef, MD<sup>6,20</sup>; Mitchell Levy, MD<sup>6,21</sup>; Edward Septimus, MD<sup>22,23</sup>; Carole VanAntwerpen, RN, BSN<sup>24,25</sup>; Don Wright, MD, MPH<sup>26</sup>; Pamela Lipsett, MD, MHPE<sup>6,27</sup>

#### *Critical Care Medicine* 2013;41:2467-2475


# An Alternative Approach to Surveillance

- Broaden the focus of surveillance from pneumonia alone to the syndrome of ventilator complications in general
  - More accurate description of what can be reliably determined using surveillance definitions
  - Emphasizes the importance of preventing *all* complications of mechanical ventilation, not just pneumonia
- Streamline the definition using quantitative criteria
  - Reduce ambiguity
  - Improve reproducibility
  - Enable electronic collection of all variables

## Ventilator-Associated Events (VAE)

Sustained rise in daily minimum PEEP >3cm or FiO2 >20 points after a period of stable or improving daily minimum PEEP or FiO2

Date	PEEP (min)	FiO2 (min)	
Jan 1	10	100	
Jan 2	5	50	
Jan 3	5	40	
Jan 4	5	40	
Jan 5	8	60	
Jan 6	8	50	VÆ
Jan 7	8	40	
Jan 8	5	40	
Jan 9	5	40	





#### nhsn.cdc.gov/VAECalculator/vaecalc.html

#### National Healthcare Safety Network (NHSN)


CDC > NHSN > Materials for Enrolled Facilities

#### NHSN Ventilator-Associated Event (VAE) Calculator Ver. 5.0

MV Day	Date	Hide (cmH <sub>2</sub> O)	Min. PEEP	Hide	Min. FiO <sub>2</sub>	VAE	T<36° or T>38°	WBC ≤ 4,000 or WBC ≥ 12,000 cells/mm <sup>3</sup>	Add Remove Choose a Drug PIPERACILLIN/TAZOBACTAM	QAD
1	4/1/2018	5		40					0	
2	4/2/2018	5		40					0	
† 3	4/3/2018	5		40						
† 4	4/4/2018	10		60		‡ IVAC				¶ yes
† 5	4/5/2018	8		50						¶ yes
† 6	4/6/2018	8		40						¶ yes
7	4/7/2018	6		40						¶ yes
8	4/8/2018	5		40						¶ yes
9	4/9/2018	5		40						¶ yes
10	4/10/2018									¶ yes


Brief report			
Assessment of an automated surveillance system for of initial ventilator-associated events	or detection		
Dooshanveer Nuckchady MD <sup>a</sup> , Michael G. Heckman MS <sup>b</sup> , Nancy Tara Creech RN <sup>c</sup> , Darlene Carey RN, MSN <sup>c</sup> , Robert Domnick BS <sup>d</sup> , Walter C. Hellinger MD <sup>a,*</sup>			
	event electronic surveillar implementation	ce system: A report of a successful	
<b>Electronic Implementation of a Novel Surve</b> <b>Paradigm for Ventilator-associated Events</b> Feasibility and Validation Peter M. C. Klein Klouwenberg <sup>1,2,3*</sup> , Maaike S. M. van Mourik <sup>1*</sup> , David S. Marcus J. Schultz <sup>4</sup> , Olaf L. Cremer <sup>2</sup> , and Marc J. M. Bonten <sup>1,3</sup> ; on penalt	. Y. Ong <sup>1,2,3</sup> , Janneke Horn <sup>4</sup> ,	hifer Flaherty RN, MPH, CIC <sup>c</sup> , I, CIC <sup>d</sup> , Jing Ding PhD <sup>e</sup> , Julie E. Mangino MD <sup>b,c</sup>	
	Building and Validating a C	omputerized Algorithm for Surveillance tor-Associated Events	
Tal		la, MD; <sup>3</sup> Anupama Neelakanta, MD, MPH; <sup>4</sup> Thomas Chevalier, BSN, CIC; <sup>2</sup> r, MD; <sup>6</sup> Mary E. Robinson, BSBA; <sup>2</sup> Keith S. Kaye, MD, MPH <sup>6</sup>	
Development, Implementation and Use of Elect Ventilator-Associated Events (VAE			
Ervina Resetar, MIM, PMP <sup>1,3</sup> , Kathleen M. McMullen, M MPH <sup>2</sup> , Joshua A. Doherty, BS <sup>3</sup> , Kathleen A. Gase, MPH,			

## Attributable Mortality of VAE versus VAP



#### Canadian Critical Care Trials Group ABATE Study

*11 ICUs, 1330 patients, VAE vs VAP Surveillance* 




Muscedere et al. Chest 2013;144:1453



#### Qualitative analysis of 153 VAEs

Royal Brisbane & Women's Hospital, Queensland, Australia




Hayashi et al. Clin Infect Dis 2013;56:471-477


# VAE = VAP +Fluid + ARDS + Atelectasis

# Fewer VAEs How do we get there?

## **Strategies for Preventing VAEs**



### **Strategies for Preventing VAEs**



## **VAE Prevention Strategies**


<i>Well aligned with other best practice initiatives</i>	ABCDE	Choosing Wisely	PAD Guidelines	Surviving Sepsis	Strategies to Prevent VAP
Minimize sedation	1	1	1	1	
Paired SATs and SBTs		1	1	1	
Early Mobility			1		
Conservative fluid management					
Conservative transfusion thresholds					

#### **Ventilator Bundle Compliance and VAEs**

Retrospective analysis of 5,539 patients on mechanical ventilation adjusted for comorbidities, severity of illness, contraindications, etc.

Spontaneous breathing trials Spontaneous awakening trials Head of bed elevation Thromboprophylaxis Stress ulcer prophylaxis Oral care with chlorhexidine

#### Hazard Ratios for VAEs




#### Ventilator Bundle Compliance and Death

Retrospective analysis of 5,539 patients on mechanical ventilation adjusted for comorbidities, severity of illness, contraindications, etc.


Spontaneous breathing trials Spontaneous awakening trials Head of bed elevation Thromboprophylaxis Stress ulcer prophylaxis Oral care with chlorhexidine

#### Hazard Ratios for Ventilator Death




- Prospective care improvement collaborative
- 12 ICUs (mix of med, surg, mixed & academic, community)
- 19 months
- Goal: prevent VAEs through earlier liberation from mechanical ventilation
- Mechanism: enhance the uptake and performance of paired daily SATs and SBTs ( "Every Patient, Every Day" )

#### SATs and SBTs




Am J Resp Crit Care Med 2015;191:292-301

#### **Ventilator-Associated Events**



Am J Resp Crit Care Med 2015;191:292-301


#### Ventilator Days and ICU Days



Am J Resp Crit Care Med 2015;191:292-301

### **Depletive Fluid Management**


- Randomized controlled trial of ventilator weaning
- 304 patients randomized to daily BNP levels versus usual care
- Patients randomized to daily BNP levels had:
  - More diuretics
  - More negative fluid balance
  - Less time to extubation
  - <u>50% fewer VAEs</u>



Mekontso Dessap et al. Chest 2014;146:58-65

#### **Two State Collaborative to Prevent VAEs**

56 ICUs in Maryland and Pennsylvania, Oct 2012 to Mar 2015



*Crit Care Med* 2017;45:1208-1215

#### Ventilator-associated events A patient safety opportunity

#### • Broaden Awareness

 Provides hospitals with a fuller picture of serious complications in mechanically ventilated patients

#### • Catalyze Prevention

• A significant portion of VAEs are preventable through well-accepted best practices in critical care

#### Reflect and Inform Progress

 VAE surveillance provides an efficient and objective yardstick to measure and benchmark progress

NEJM 2013;368:1472

## Summary

- VAP is a **poor metric for benchmarking** and quality improvement
  - Diagnosis subjective and inaccurate
  - High interobserver variability
  - Poor guide to selecting prevention practices that will improve patient outcomes
- CDC created **ventilator-associated event definitions** to enhance objectivity, automation, and expand prevention efforts
  - Suitable for automated surveillance
- Lower VAE rates and improve outcomes by implementing strategies to reduce duration of mechanical ventilation and prevent the primary conditions associated with VAEs (pneumonia, ARDS, atelectasis, edema)
  - Minimize sedation
  - Paired daily SATs and SBTs
  - Early mobility
  - Conservative fluid management
  - Minimize blood transfusions

#### Thank You!

mklompas@bwh.harvard.edu